- Conditions
- Multiple Sclerosis, Myasthenia Gravis
- Interventions
- CC-97540, Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Irvine, California • Aurora, Colorado + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 145
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- FCR001
- Biological
- Lead sponsor
- Talaris Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 889 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Interventions
- Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, Placebo, MRI contrast-enhancing agents
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- Idebenone, placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- Avonex® monotherapy (6.0 MIU administered i.m. each week)
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 43
- States / cities
- Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
- Conditions
- Multiple Sclerosis
- Interventions
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- Obecabtagene autoleucel (obe-cel)
- Biological
- Lead sponsor
- Autolus Limited
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Foralumab, Placebo
- Drug · Other
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis Brain Lesion, Multiple Sclerosis Benign
- Interventions
- Clemastine Fumarate, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Ocrelizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,013 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more
- Conditions
- Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Remibrutinib (Open Label)
- Drug
- Lead sponsor
- Moein Amin
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)
- Biological · Drug
- Lead sponsor
- Bruce Cree
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Multiple Sclerosis Center of Northeastern New York
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
- Interventions
- Intravenous and Intranasal BMSC
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Orelabrutinib, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 8 more
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD, EHP-101 50 mg BID
- Drug
- Lead sponsor
- Emerald Health Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Cullman, Alabama • Fullerton, California • Port Orange, Florida
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Orelabrutinib, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 9 more